Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Firuglipel

    go.drugbank.com/drugs/DB19506
    Investigational

    Firuglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is a small molecule drug. Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).

  2. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.

  3. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections.

  4. Drug

    Tonapofylline

    go.drugbank.com/drugs/DB12569
    Investigational

    Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.

    Categories: Receptor, Adenosine A1
  5. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative. … [A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute.

  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  7. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. … [L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs).

  8. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

  9. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  10. Drug

    Calcipotriol

    go.drugbank.com/drugs/DB02300
    ApprovedInvestigational

    Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

    Mixtures: Enstilar 50 Mikrogramm/g + 0,5 mg/g Schaum zur Anwendung auf der HautCategories: Vitamin D and Analogues